Collectively, these findings demonstrate that METTL3 promotes pathological lung remodeling through multiple m6A-dependent mechanisms and represents a promising epigenetic therapeutic target in pulmonary fibrosis. The gene discussed is METTL3; the disease is pulmonary fibrosis.